These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

833 related items for PubMed ID: 30119633

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
    Liang J, Mesplède T, Oliveira M, Anstett K, Wainberg MA.
    J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
    [Abstract] [Full Text] [Related]

  • 3. Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.
    Hassounah SA, Alikhani A, Oliveira M, Bharaj S, Ibanescu RI, Osman N, Xu HT, Brenner BG, Mesplède T, Wainberg MA.
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923862
    [Abstract] [Full Text] [Related]

  • 4. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
    Tsiang M, Jones GS, Goldsmith J, Mulato A, Hansen D, Kan E, Tsai L, Bam RA, Stepan G, Stray KM, Niedziela-Majka A, Yant SR, Yu H, Kukolj G, Cihlar T, Lazerwith SE, White KL, Jin H.
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7086-7097. PubMed ID: 27645238
    [Abstract] [Full Text] [Related]

  • 5. HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants.
    Smith SJ, Zhao XZ, Passos DO, Lyumkis D, Burke TR, Hughes SH.
    Antimicrob Agents Chemother; 2020 Aug 20; 64(9):. PubMed ID: 32601157
    [Abstract] [Full Text] [Related]

  • 6. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
    Anstett K, Fusco R, Cutillas V, Mesplède T, Wainberg MA.
    J Virol; 2015 Oct 20; 89(20):10482-8. PubMed ID: 26246578
    [Abstract] [Full Text] [Related]

  • 7. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
    Santoro MM, Fornabaio C, Malena M, Galli L, Poli A, Menozzi M, Zazzi M, White KL, Castagna A, PRESTIGIO Study Group.
    Int J Antimicrob Agents; 2020 Jul 20; 56(1):106027. PubMed ID: 32450199
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
    Osman N, Mesplède T, Oliveira M, Hassounah S, Wainberg MA, Brenner BG.
    AIDS; 2018 Aug 24; 32(13):1773-1780. PubMed ID: 29894388
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes.
    Neogi U, Singh K, Aralaguppe SG, Rogers LC, Njenda DT, Sarafianos SG, Hejdeman B, Sönnerborg A.
    AIDS; 2018 Feb 20; 32(4):469-476. PubMed ID: 29239896
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.
    Hassounah SA, Mesplède T, Quashie PK, Oliveira M, Sandstrom PA, Wainberg MA.
    J Virol; 2014 Sep 01; 88(17):9683-92. PubMed ID: 24920794
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.
    Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, Ye L, Niedziela-Majka A, Barnes TL, Novikov N, Chen X, Svarovskaia ES, McColl DJ, White KL, Miller MD.
    Antimicrob Agents Chemother; 2013 Jun 01; 57(6):2654-63. PubMed ID: 23529738
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.
    Seki T, Suyama-Kagitani A, Kawauchi-Miki S, Miki S, Wakasa-Morimoto C, Akihisa E, Nakahara K, Kobayashi M, Underwood MR, Sato A, Fujiwara T, Yoshinaga T.
    Antimicrob Agents Chemother; 2015 May 01; 59(5):2596-606. PubMed ID: 25691633
    [Abstract] [Full Text] [Related]

  • 20. Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials.
    You J, Wang H, Huang X, Qin Z, Deng Z, Luo J, Wang B, Li M.
    PLoS One; 2016 May 01; 11(8):e0160087. PubMed ID: 27532886
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.